How does eteplirsen actually help a boy with Duchenne muscular dystrophy keep walking longer?
Eteplirsen is a short genetic instruction (antisense oligonucleotide) that tells muscle cells to skip over a broken gene section, allowing them to make a shorter but still-working muscle protein. In boys with exon 51-amenable DMD, 71% remained walking at 48 weeks vs. 32% in historical controls—a 39-point gain [5].
In Duchenne muscular dystrophy, a mutation breaks the gene that makes dystrophin, a protein that protects muscle fibers. Eteplirsen works by binding to the messenger RNA (the cell's instruction copy) and telling the cell to skip the broken section, so the muscle can still make a shorter dystrophin protein that works [1]. This shorter protein is not perfect, but it is enough to slow muscle damage.
Once injected into the bloodstream, eteplirsen travels to muscle cells and binds to the faulty messenger RNA within hours. The drug is cleared from the body within days, but the muscle cells keep making the shorter dystrophin protein for weeks [3]. This steady production of working protein slows the breakdown of muscle fibers and delays the loss of walking ability.
Real-world benefit: boys on eteplirsen stay ambulatory (walking) 1–2 years longer than boys in historical control groups [7]. However, the drug only works if the genetic deletion is in the right spot—exon 51 or an exon 51-skip-equivalent deletion. About 13% of DMD boys have this specific deletion type [8]. If your son's deletion is elsewhere, other antisense drugs or gene therapies may be options.
Ask your neurologist: 'Has genetic testing confirmed my son's exact deletion, and is it exon 51-amenable or exon 51-skip-equivalent?' If yes, eteplirsen is worth discussing. If no, ask about other antisense oligonucleotides (golodirsen for exon 53, viltolarsen for exon 53) or gene therapy trials.